J&J's oral IL-23 inhibitor ICOTYDE showed sustained skin clearance through Week 112 in Phase 3 plaque psoriasis, including at high-impact sites like scalp, genitals, hands and feet. An oral option com

What happened: Johnson & Johnson reported new Phase 3 results for its oral IL-23 inhibitor ICOTYDE in plaque psoriasis at the 2026 EADV Congress, showing sustained skin clearance and improvement at high-impact sites, including in adolescent patients. Key numbers: Sustained skin clearance Why it matters: The content frames an oral option competing with injectable biologics as a pipeline catalyst for $JNJ, with ongoing trials in psoriatic arthritis, ulcerative colitis and Crohn's disease. The stated next test is how the evidence translates into prescribing and reimbursement decisions.

Johnson & Johnson reported new Phase 3 results for its oral IL-23 inhibitor ICOTYDE in plaque psoriasis at the 2026 EADV Congress, showing sustained skin clearance and improvement at high-impact sites, including in adolescent patients.

The content frames an oral option competing with injectable biologics as a pipeline catalyst for $JNJ, with ongoing trials in psoriatic arthritis, ulcerative colitis and Crohn's disease. The stated next test is how the evidence translates into prescribing and reimbursement decisions.